This trial is testing a new drug for patients with multiple myeloma who have run out of other treatment options. They will establish a safe dose and look at how the drug works in the body.
- Relapsed or Refractory Multiple Myeloma
3 Primary · 3 Secondary · Reporting Duration: 36 months
2 Treatment Groups
1 of 2
1 of 2
48 Total Participants · 2 Treatment Groups
Primary Treatment: ORIC-533 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are the researchers currently recruiting participants for this research project?
"Affirmative. Clinicaltrials.gov records indicate that this clinical trial, which was first posted on June 1st 2022 is currently in the process of patient recruitment. The research team needs to recruit 48 volunteers across 2 sites for further study participation." - Anonymous Online Contributor
How many participants will this clinical trial involve?
"Affirmative. Clinicaltrials.gov data reveals that this trial, posted on January 6th 2022 and last updated February 2nd 2022, is actively recruiting candidates. The study requires 48 patients from two distinct sites to participate." - Anonymous Online Contributor
What are the attendant risks of utilizing ORIC-533 to treat patients?
"Due to the early stage of clinical trials, ORIC-533's safety has been provisionally assessed as a 1. This is reflective of limited data that supports its efficacy and protection from harm." - Anonymous Online Contributor